Mallinckrodt Plc (MNK)

3.30
NYSE : Health Technology
Prev Close 2.99
Day Low/High 2.98 / 3.65
52 Wk Low/High 1.43 / 32.50
Avg Volume 6.67M
Exchange NYSE
Shares Outstanding 84.01M
Market Cap 251.19M
EPS -42.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dow Finishes Up, Stocks Mixed as Apple Unveils iPhone 11 and Apple+ TV

Dow Finishes Up, Stocks Mixed as Apple Unveils iPhone 11 and Apple+ TV

Stocks finished mixed Tuesday with tech stocks leading decliners as Apple unveiled its iPhone 11 and announced that its Apple TV+ streaming service will $4.99 per month.

Mallinckrodt to Sell BioVectra Unit to H.I.G. Capital for $250 Million

Mallinckrodt to Sell BioVectra Unit to H.I.G. Capital for $250 Million

Shares of the troubled drugmaker jump after the company announces a deal to sell its contract development and manufacturing subsidiary BioVectra.

Mallinckrodt Agrees To Sell BioVectra Inc. To H.I.G. Capital For $250 Million

Mallinckrodt Agrees To Sell BioVectra Inc. To H.I.G. Capital For $250 Million

-- Transaction continues to advance Mallinckrodt's strategic focus on branded biopharmaceuticals by monetizing a non-core business --

S&P Dow Jones Indices Announces Nine Companies Set To Join S&P MidCap 400; Ten Companies To Join S&P SmallCap 600

S&P Dow Jones Indices Announces Nine Companies Set To Join S&P MidCap 400; Ten Companies To Join S&P SmallCap 600

NEW YORK, Sept. 6, 2019 /PRNewswire/ -- S&P Dow Jones Indices will make the following index adjustments to the S&P MidCap 400 and S&P SmallCap 600 to ensure each index more appropriately represents its market capitalization range.

Mallinckrodt Shares Jump as Pharma Giant Settles Ohio Opioid Lawsuits

Mallinckrodt Shares Jump as Pharma Giant Settles Ohio Opioid Lawsuits

In its pending settlement agreement with Cuyahoga and Summit counties, Mallinckrodt has agreed to pay $24 million cash and $6 million in generic products, including products for addiction treatment.

Mallinckrodt Announces Settlement In Principle To Resolve "Track 1" Opioid Cases With The Ohio Counties Of Cuyahoga And Summit

Mallinckrodt Announces Settlement In Principle To Resolve "Track 1" Opioid Cases With The Ohio Counties Of Cuyahoga And Summit

-- Dismisses all named Mallinckrodt entities with prejudice from the lawsuit --

Interesting MNK Put And Call Options For October 25th

Interesting MNK Put And Call Options For October 25th

Investors in Mallinckrodt plc saw new options become available today, for the October 25th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new October 25th contracts and identified one put and one call contract of particular interest.

Mallinckrodt Plunges on Report It's Considering Filing for Bankruptcy

Mallinckrodt Plunges on Report It's Considering Filing for Bankruptcy

Shares of drugmaker Mallinckrodt plunge on a report the company is considering filing for bankruptcy as a way of dealing with its opioid-related legal liabilities.

Interesting MNK Put And Call Options For October 11th

Interesting MNK Put And Call Options For October 11th

Investors in Mallinckrodt plc saw new options begin trading today, for the October 11th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new October 11th contracts and identified one put and one call contract of particular interest.

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

These Drug Cos. Could Soon Feel Big Side Effects of Opioid Crisis

No company is safe from the litigation risk tied to the drug epidemic, but Johnson & Johnson may be one of the few guaranteed to survive.

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Johnson & Johnson Rises on $572 Million Fine That's Smaller Than Feared

Wall Street expects the healthcare giant can take the jolt from the penalty delivered by an Oklahoma judge in the state's opioid case against J&J.

Interesting MNK Put And Call Options For October 4th

Interesting MNK Put And Call Options For October 4th

Investors in Mallinckrodt plc saw new options begin trading today, for the October 4th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new October 4th contracts and identified one put and one call contract of particular interest.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Mallinckrodt Plc Of Class Action Lawsuit And Upcoming Deadline - MNK

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Mallinckrodt Plc Of Class Action Lawsuit And Upcoming Deadline - MNK

NEW YORK, Aug. 24, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (" Mallinckrodt" or the "Company") (NYSE:  MNK) and certain of its officers.

Mallinckrodt To Present At Morgan Stanley 17th Annual Global Healthcare Conference

Mallinckrodt To Present At Morgan Stanley 17th Annual Global Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, Aug. 21, 2019 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, Sept.

Interesting MNK Put And Call Options For April 2020

Interesting MNK Put And Call Options For April 2020

Investors in Mallinckrodt plc saw new options become available this week, for the April 2020 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Notable Thursday Option Activity: MNK, CORR, SO

Notable Thursday Option Activity: MNK, CORR, SO

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Mallinckrodt plc , where a total of 87,252 contracts have traded so far, representing approximately 8.7 million underlying shares. That amounts to about 193.8% of MNK's average daily trading volume over the past month of 4.5 million shares.

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Mallinckrodt Plc

Glancy Prongay & Murray Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Mallinckrodt Plc

Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming September 24, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK) investors who purchased...

Mallinckrodt Announces Positive Top-Line Results From Its Pivotal Phase 3 CONFIRM Trial Of Terlipressin In Patients With Hepatorenal Syndrome Type 1 (HRS-1)

Mallinckrodt Announces Positive Top-Line Results From Its Pivotal Phase 3 CONFIRM Trial Of Terlipressin In Patients With Hepatorenal Syndrome Type 1 (HRS-1)

-- Study met primary endpoint, verified HRS-1 reversal including three components: renal function improvement, avoidance of dialysis and short-term survival --

Mallinckrodt Announces Publication Of Results Of Phase 1b Clinical Trial Of StrataGraft® Regenerative Tissue In Burns

Mallinckrodt Announces Publication Of Results Of Phase 1b Clinical Trial Of StrataGraft® Regenerative Tissue In Burns

- Study results showed that StrataGraft-treated deep partial-thickness burns did not require surgical harvest of healthy skin by 28 days -

Interesting MNK Put And Call Options For September 27th

Interesting MNK Put And Call Options For September 27th

Investors in Mallinckrodt plc saw new options begin trading today, for the September 27th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MNK options chain for the new September 27th contracts and identified one put and one call contract of particular interest.

First Patient Enrolled In Mallinckrodt's Phase 2a Study Of Investigational Drug MNK-6106 In Hepatic Cirrhosis And Chronic Hepatic Encephalopathy (HE)

First Patient Enrolled In Mallinckrodt's Phase 2a Study Of Investigational Drug MNK-6106 In Hepatic Cirrhosis And Chronic Hepatic Encephalopathy (HE)

-- Trial is to Assess Pharmacokinetics, Pharmacodynamics and Safety of the Oral Administration of MNK-6106 in Patients with HE --

ROSEN, A TOP RANKED LAW FIRM, Reminds Mallinckrodt Plc Investors Of Important Deadline In Securities Class Action; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - MNK

ROSEN, A TOP RANKED LAW FIRM, Reminds Mallinckrodt Plc Investors Of Important Deadline In Securities Class Action; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - MNK

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mallinckrodt plc (NYSE: MNK) from February 28, 2018 through July 16, 2019, inclusive (the "Class Period") of the important September 24, 2019 lead plaintiff...

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Mallinckrodt Plc Investors (MNK)

INVESTOR ALERT: Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of Mallinckrodt Plc Investors (MNK)

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Mallinckrodt plc ("Mallinckrodt" or the "Company") (NYSE: MNK) securities between February 28, 2018 and July 16, 2019, inclusive (the...

Mallinckrodt Plc Reports Strong Results In Second Quarter 2019, Raises Adjusted EPS Guidance For 2019, And Announces Suspension Of Specialty Generics Spin-off

Mallinckrodt Plc Reports Strong Results In Second Quarter 2019, Raises Adjusted EPS Guidance For 2019, And Announces Suspension Of Specialty Generics Spin-off

- Net sales of $823.3 million, led by continued strong growth across its hospital portfolio and AMITIZA® (lubiprostone), and continued growth in the Specialty Generics segment

Mallinckrodt To Present At Wells Fargo Securities 2019 Healthcare Conference

Mallinckrodt To Present At Wells Fargo Securities 2019 Healthcare Conference

STAINES-UPON-THAMES, United Kingdom, Aug. 2, 2019 /PRNewswire/ --  Mallinckrodt Pharmaceuticals (NYSE: MNK), a global biopharmaceutical company, will present on Thursday, Sept.

ROSEN, A LEADING LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Mallinckrodt Plc; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - MNK

ROSEN, A LEADING LAW FIRM, Announces Filing Of Securities Class Action Lawsuit Against Mallinckrodt Plc; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - MNK

NEW YORK, July 31, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Mallinckrodt plc (NYSE: MNK) from February 28, 2018 through July 16,...

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Mallinckrodt Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces The Filing Of A Class Action Lawsuit Against Mallinckrodt Plc And Encourages Investors With Losses In Excess Of $100,000 To Contact The Firm

The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Mallinckrodt plc ("Mallinckrodt" or "the Company") (NYSE: MNK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of...

TheStreet Quant Rating: D (Sell)